Bristol Adds Diabetes Class Warning To Abilify Labeling; “Paucity” Of Reports Cited For Antipsychotic
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol and Otsuka had been seeking to persuade FDA that the atypical antipsychotic should be exempt from a class-wide hyperglycemia warning. Bristol will continue discussions with the agency as new data become available.